


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: <u>June 23, 2004</u> (use as many sheets as necessary)				<b>Complete if Known</b> Application Number: 09/913,728 Filing Date: 10/23/2001 First Named Inventor: Toshio KITAMURA et al. Group Art Unit: 1647 Examiner Name: R. DeBerry Attorney Docket Number: 084335-0143	
Sheet	1	of	1		



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>3</sup>
	A1	LUO, Hong, et al., "An amino acid substitution in the <i>Drosophila hop<sup>1</sup>um-1</i> Jak kinase causes leukemia-like hematopoietic defects", <u>The EMBO Journal</u> , vol. 14, no. 7, pp 1412-1420, Oxford University Press, 1995			
	A2	LACRONIQUE, Virginie, et al., "A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia", <u>Science</u> , vol. 278, Nov. 14, 1997, pp 1309-1312			
	A3	MEYDAN, Naftaly, et al., "Inhibition of acute lymphoblastic leukaemia by a JAK-2 inhibitor", <u>Nature</u> , vol. 379, Feb. 15, 1996, pp 645-648			

Examiner Signature		Date Considered	8/11/04
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.